

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Diagnamed Holdings Corp.** (the "Issuer")

Trading Symbol: DMED

Number of Outstanding Listed Securities: **76,222,085**

Date: **February 3, 2023**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
During the month, the issuer continued to work for the development and commercialization of intellectual property of a novel virtual reality and artificial intelligence neurodiagnostic system ("VR/AI Neuro") for the evaluation, diagnosis and monitoring of neurodegenerative diseases.

2. Provide a general overview and discussion of the activities of management.

On January 30th, the Issuer filed its Annual Financial Statements and Management Discussion and Analysis on SEDAR. The above were filed on the CSE and OTCQB websites and at www.sedar.com.

On January 31st, the Issuer announced that provided an update on its development and commercialization plans and expected milestones in 2023 for BRAIN AGE™, a proprietary electroencephalogram-based (“EEG”) artificial intelligence solution to detect and monitor an individual’s brain age, as a potential brain health solution for athletes, and those diagnosed with a mental health and neurodegenerative condition.

Development Update

The Company entered into an exclusive worldwide license agreement with Drexel University for the intellectual property of BRAIN AGE™. In addition, it commenced late-stage development under a sponsored research agreement led by Dr. John Kounios, PhD, Professor of Psychological and Brain Sciences at Drexel University. The current development of BRAIN AGE™ is focused on integrating its software components into a unified turnkey pipeline, developing a standardized EEG recording protocol, collecting new EEG data from an ongoing research study, and using the latest data to validate the BRAIN AGE™ machine learning model for regulatory marketing authorization in the U.S.

Expected Milestones and Market Opportunity

In Q2-2023, the Company expects to complete its IRB-approved research study involving 100 subjects assessing the stability and reliability of BRAIN AGE™ over time which would finalize the headset, software, and brain age estimation modules. Once this is completed and if successful, the Company will seek to obtain regulatory authorization to market BRAIN AGE™ as a clinical tool in the U.S. by Q4-2023.

Commercialization and Market Opportunity

The Company is preparing for the build-out of its BRAIN AGE™ clinical provider network, which would be comprised of up to 10,000 licensed physicians, specialists (i.e. mental health, neurology) and sports clinics in the U.S. where the BRAIN AGE™ solution could be offered to eligible

patients. The Company believes that the potential initial target market population for BRAIN AGE™, comprised of athletes, mental health and neurodegenerative patients, is at least 50 million in the U.S. alone.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not Applicable

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable

8. Describe the acquisition of new customers or loss of customers.

Not Applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

See item #1.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A	N/A	N/A	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

Not Applicable

16. Provide details of any changes in directors, officers or committee members.

Not Applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Not Applicable.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there was no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **February 3, 2023**

Fabio Chianelli

Name of Director or Senior Officer

"Fabio Chianelli"

Signature

Chief Executive Officer

Official Capacity

<i>Issuer Details</i> Name of Issuer Diagnamed Holdings Corp.	For Month End January 2023	Date of Report YY/MM/DD 2023/02/03
Issuer Address 2900 - 550 Burrard Street		
City/Province/Postal Code Vancouver, British Columbia V6C 0A3	Issuer Fax No.	Issuer Telephone No. 416 800-2684
Contact Name Fabio Chianelli	Contact Position CEO	Contact Telephone No. 416 800-2684
Contact Email Address info@diagnamed.com	Web Site Address www.diagnamed.com	